Limits of diagnosis and molecular markers for early detection of ulcerative colitis-associated colorectal neoplasia

Digestion
Shigehiko FujiiT Fujimori

Abstract

The incidence of colorectal neoplasia has been increasing among patients with long-standing and extensive ulcerative colitis (UC), and therefore surveillance colonoscopy has been widely recommended. However, because UC-associated neoplasia is often difficult to detect endoscopically and to discriminate from inflammatory regenerative epithelium histologically, the efficacy of current surveillance remains unsatisfactory. In order to overcome these difficulties, adjunctive modalities for diagnosing UC-associated neoplasia, chromo- and magnifying endoscopy for endoscopic diagnosis and analysis of p53 alteration for histological diagnosis have been introduced. Furthermore, if it were possible to differentiate UC patients with long-standing and extensive colitis into subgroups with a high and a low risk of neoplasia, it would enable physicians to conduct more intensive surveillance with these modalities for patients at higher risk. Several molecular alterations of nonneoplastic epithelium in UC patients with neoplasia may be promising as markers for identifying individuals with UC at increased risk of neoplasia. We evaluated estrogen receptor (ER) methylation of nonneoplastic colorectal epithelium to clarify whether this epigenetic a...Continue Reading

References

Nov 1, 1992·Gastroenterology·E LangholzV Binder
Nov 1, 1990·The New England Journal of Medicine·A EkbomH O Adami
Oct 1, 1988·Histopathology·M F DixonG T Williams
Jul 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G N TytgatN Gopinath
Oct 1, 1994·Journal of Clinical Pathology·S KudoA Yagyuu
Feb 18, 1999·The American Journal of Gastroenterology·B A LashnerJ R Goldblum
Feb 7, 2002·Lancet·Richard J Farrell, Mark A Peppercorn
Apr 26, 2002·Pathology International·Shigehiko FujiiHiroshi Kashida
Jul 19, 2002·Gastroenterology Clinics of North America·Rupam Sharan, Robert E Schoen
Oct 2, 2002·Nature Genetics·Jacintha N O'SullivanPeter S Rabinovitch
Feb 3, 2004·Gastroenterology·Keisuke HataHirokazu Nagawa
Mar 1, 2005·Inflammatory Bowel Diseases·Steven H ItzkowitzUNKNOWN Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group
Dec 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keiichi TominagaTakahiro Fujimori
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Toshiaki WatanabeHirokazu Nagawa

❮ Previous
Next ❯

Citations

Aug 11, 2011·Inflammatory Bowel Diseases·Shunsuke SaitoKazuhide Yamamoto
Jun 8, 2011·Nature Reviews. Gastroenterology & Hepatology·Sigrun ThorsteinsdottirJakob Benedict Seidelin
Oct 26, 2012·QJM : Monthly Journal of the Association of Physicians·P J Trivedi, B Braden
Nov 2, 2011·The Tohoku Journal of Experimental Medicine·Yasuhiro YamamotoHarumoto Yamada
Jun 3, 2011·World Journal of Gastroenterology : WJG·Hala E HamoudaWael W Mayah
Aug 19, 2014·World Journal of Gastroenterology : WJG·Triana LobatónGabriel Capellá
Jul 21, 2010·Clinical Colorectal Cancer·Daniel AzuaraGabriel Capellá
Jul 28, 2019·Oral Diseases·Gauravi A MishraSubhadra D Gupta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.